
|Videos|December 7, 2016
A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin Lymphoma
Author(s)Alex Herrera, MD
Alex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.


















